Katy Beckermann, MD, PhD, is an assistant professor of medicine at Vanderbilt University Medical Center, and medical director of genitourinary clinical research at Tennessee Oncology.
PROs Similar With Tivozanib Monotherapy vs Combination in RCC
Patient-reported outcomes (PROs) were similar among those treated with tivozanib monotherapy and those given combination tivozanib and nivolumab in for renal cell carcinoma (RCC) in the TiNivo-2 study, according to a poster presented at the American Society of Clinical Oncology Genitourinary Cancers Symposium by Katy Beckermann, MD, PhD.